ES2159967T3 - Medicamento que contiene acido delta-aminolevulinico. - Google Patents

Medicamento que contiene acido delta-aminolevulinico.

Info

Publication number
ES2159967T3
ES2159967T3 ES98952606T ES98952606T ES2159967T3 ES 2159967 T3 ES2159967 T3 ES 2159967T3 ES 98952606 T ES98952606 T ES 98952606T ES 98952606 T ES98952606 T ES 98952606T ES 2159967 T3 ES2159967 T3 ES 2159967T3
Authority
ES
Spain
Prior art keywords
aminolevulinic acid
medicament
containing delta
delta
medicinal containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98952606T
Other languages
English (en)
Inventor
Wolfgang Heisig
Ferdinand Bach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Original Assignee
Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medac Gesellschaft fuer Klinische Spezialpraeparate mbH filed Critical Medac Gesellschaft fuer Klinische Spezialpraeparate mbH
Application granted granted Critical
Publication of ES2159967T3 publication Critical patent/ES2159967T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Medicamento de aplicación tópica para el diagnóstico integral y/o la terapia de tumores en órganos huecos a base de ácido -aminolevulínico, caracterizado porque contiene ácido -aminolevulínico en una solución acuosa que está ajustada mediante un ácido siológicamente tolerable y sodiohidrogenfosfato a un valor pH de 4,8 a 5,2.
ES98952606T 1997-10-02 1998-09-21 Medicamento que contiene acido delta-aminolevulinico. Expired - Lifetime ES2159967T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19744811A DE19744811C2 (de) 1997-10-02 1997-10-02 Verwendung von delta-Aminolävulinsäure zur Herstellung eines topischen Arzneimittels zur integralen Diagnose und/oder Therapie von Tumoren in Hohlorganen

Publications (1)

Publication Number Publication Date
ES2159967T3 true ES2159967T3 (es) 2001-10-16

Family

ID=7845169

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98952606T Expired - Lifetime ES2159967T3 (es) 1997-10-02 1998-09-21 Medicamento que contiene acido delta-aminolevulinico.

Country Status (13)

Country Link
EP (1) EP1019037B9 (es)
JP (1) JP2001518498A (es)
AT (1) ATE203903T1 (es)
AU (1) AU729973B2 (es)
DE (2) DE19744811C2 (es)
DK (1) DK1019037T3 (es)
ES (1) ES2159967T3 (es)
GR (1) GR3036481T3 (es)
NZ (1) NZ503802A (es)
PT (1) PT1019037E (es)
TR (1) TR200000890T2 (es)
WO (1) WO1999017764A1 (es)
ZA (1) ZA988820B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009212A1 (en) * 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
JP5081121B2 (ja) * 2008-10-17 2012-11-21 株式会社ミルボン 育毛剤組成物
US10675242B2 (en) 2016-09-02 2020-06-09 Sbi Pharmaceuticals, Co., Ltd. Aqueous formulation containing 5-aminolevulinic acid or the like
RU2630124C1 (ru) * 2016-10-06 2017-09-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ интраоперационной диагностики и лечения злокачественных новообразований органов брюшной полости
CN115671059B (zh) * 2022-11-17 2024-06-11 兆科药业（合肥）有限公司 一种盐酸氨酮戊酸冻干制剂及制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5026825A (en) * 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5079262A (en) * 1989-07-28 1992-01-07 Queen's University At Kingston Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid
FR2690340B1 (fr) * 1992-04-24 1995-02-24 Scr Newmed Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
DE4228106A1 (de) * 1992-08-24 1994-03-03 Medac Klinische Spezialpraep Verwendung von £-Aminolävulinsäure zur Herstellung eines topischen Arzneimittels zur integralen Diagnose und/oder Therapie von Tumoren in Hohlorganen
DE4320871C2 (de) * 1993-06-24 1995-05-04 Beiersdorf Ag Kosmetische und dermatologische Zubereitungen mit einem Gehalt an delta-Aminolävulinsäure
PH31226A (en) * 1993-08-19 1998-05-12 Blazley Design Pty Ltd Explosion resistant building structures.
GB9318841D0 (en) * 1993-09-10 1993-10-27 Res Foundation Of The Norwegia Composition
CA2158724A1 (en) * 1994-09-20 1996-03-21 Jue-Chen Liu Transdermally active pharmaceutical composition containing 5-aminolaevulinic acid

Also Published As

Publication number Publication date
DE59801192D1 (de) 2001-09-13
AU1024299A (en) 1999-04-27
JP2001518498A (ja) 2001-10-16
TR200000890T2 (tr) 2000-08-21
DK1019037T3 (da) 2001-10-01
EP1019037A1 (de) 2000-07-19
GR3036481T3 (en) 2001-11-30
ATE203903T1 (de) 2001-08-15
ZA988820B (en) 1999-04-06
EP1019037B1 (de) 2001-08-08
AU729973B2 (en) 2001-02-15
DE19744811C2 (de) 1999-11-18
EP1019037B9 (de) 2002-04-17
NZ503802A (en) 2000-12-22
DE19744811A1 (de) 1999-04-15
PT1019037E (pt) 2001-11-30
WO1999017764A1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
GB0105772D0 (en) Use
SE0001899D0 (sv) New compounds
ES2177323T3 (es) Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
BR9810062A (pt) Composição cosmética contendo um agente alvejante, bem como uso de uma fonte de água em combinação com a mesma
PL357132A1 (en) Stable, nasally, orally or sublingually applicable pharmaceutical preparation
FR2634376B1 (fr) Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
CA2396186A1 (en) Agents for the treatment of skin disorders
NO20022201L (no) Lösninger inneholdende Epinastin
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
NZ507203A (en) Use of dexmedetomidine for ICU sedation
ES2159967T3 (es) Medicamento que contiene acido delta-aminolevulinico.
ES2052000T3 (es) Procedimiento para preparar composiciones farmaceuticas que contienen pentamidina.
EP1108429A3 (en) An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases
YU13599A (sh) Primena farmaceutske kompozicije za dobijanje leka u obliku gela
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
HUP9802005A2 (hu) Nátrium/hidrogén-csere inhibitorok alkalmazása különböző anyagok által a szívre gyakorolt nem kívánt hatások csökkentésére alkalmas gyógyszerkészítmények előállítására
ATE258046T1 (de) Pharmazeutische, metamizol enthaltende brauseformulierung
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
NZ505080A (en) Pharmaceutical formulations containing a compound having an amidine group stabilized by an acid
DE3865642D1 (de) Pharmazeutische zubereitung zur cholelitholyse.
ES2065308T1 (es) Producto para el moldeado permanente del cabello y nuevos esteres de acido 2-hidroxi-3-mercaptopropionico reductores de la queratina capilar.
ATE77238T1 (de) Primycin-loesungen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1019037

Country of ref document: ES